PI3K/mTOR-IN-19

PI3K/mTOR-IN-19 is an orally active, potent, selective PI3K (IC50 = 4.23 nM) and mTOR (IC50 = 2.3 nM) inhibitor. PI3K/mTOR-IN-19 significantly inhibits Eca109 cell viability and induces apoptosis. PI3K/mTOR-IN-19 causes G0/G1 cell cycle arrest, decreased mitochondrial membrane potential, and demonstrates marked telomerase inhibitory activity. PI3K/mTOR-IN-19 modulates the expression of key apoptotic regulators (Bcl-2, Bax, and p53) and downregulates the PI3K/Akt/mTOR signaling pathway. PI3K/mTOR-IN-19 can be used for the study of esophageal cancer[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Bcl-2 Family; MDM-2/p53; Mitochondrial Metabolism; mTOR; PI3K; Telomerase

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; PI3K/Akt/mTOR

Field of Research

Cancer; Inflammation/Immunology

Smiles

O=C(OCCN(CC)CC)C1=CC=C(N2N=NC(C3=NOC(C4=CC=C(F)C=C4)=C3)C2C)C=C1

Molecular Formula

C25H28FN5O3

Molecular Weight

465.52

References & Citations

[1]Sheng Y, et al. Design, synthesis, and biological evaluation of procaine-based triazole-isoxazoline hybrids as selective PI3K/mTOR inhibitors for esophageal cancer therapy: in vitro and in vivo studies. RSC Med Chem. 2025 Oct 15.